Sully.ai vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF healthcare AutonomousOS automating clinical documentation and prior auth for hospitals; YC $30.5M Sequoia Scout/AUM Ventures Series A Jan 2025 competing with Nuance DAX and Abridge for AI-powered physician workflow automation.
About
Sully.ai is a San Francisco-based healthcare AI company — backed by Y Combinator with $30.5 to $32.1 million raised including a $21.83 million Series A in January 2025 from AUM Ventures, Leonis Capital, SemperVirens VC, and Sequoia Scout Fund — providing hospitals, physician practices, and health systems with an AutonomousOS platform that automates clinical documentation (ambient AI scribing that generates SOAP notes from patient-physician conversations), administrative workflows (prior authorization processing, insurance eligibility verification, scheduling automation), and revenue cycle management tasks that consume 30-40% of physician time and hospital administrative labor. Founded in 2023 by Ahmed Nasser and Ahmed Omar, Sully.ai has 49 employees and serves healthcare providers globally with AI agents that autonomously execute multi-step clinical and administrative processes without requiring physician or staff intervention.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.